By CenterWatch, Inc.

closed 7/20/2017 via PR Newswire

CenterWatch, Inc., acquired FDAnews inc.

synopsis: WIRB-Copernicus Group, the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research, announced that it has acquired FDAnews, which provides global regulatory information for executives in the clinical research, biopharmaceutical and medical device industries.
buyer parent: Arsenal Capital Partners
buyer: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers. "
target: FDAnews inc.
FDAnews provides domestic and international regulatory, legislative and business news and information for executives in industries regulated by the U.S. Food and Drug Administration.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/5/2010 via Company Press Release

Kenneth Getz, acquired CenterWatch, Inc.

synopsis: Ken Getz, the founder of CenterWatch—an industry-leading clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information.
buyer: Kenneth Getz
Ken Getz founded CenterWatch in 1994 and established the company as a leading provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. "
target parent: Wicks Group of Companies
target: CenterWatch, Inc.
CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, data about the global clinical trials industry and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2007 via Berkery

Jobson Medical Information LLC, acquired CenterWatch, Inc.

synopsis: The Thomson Corporation announced the sale of CenterWatch to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
buyer parent: The Wicks Group of Companies, L.L.C.
buyer: Jobson Medical Information LLC
Jobson Medical Information is a leading specialty healthcare communications, publishing, and medical education company. Jobson Medical Information produces a broad range of publications, educational programs, enduring educational materials, live events, symposia and websites. "
target parent: Thomson Corporation
target: CenterWatch, Inc.
CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
closed 5/5/2010 via Company Press Release

Kenneth Getz, acquired CenterWatch, Inc.

synopsis: Ken Getz, the founder of CenterWatch—an industry-leading clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information.
buyer: Kenneth Getz
Ken Getz founded CenterWatch in 1994 and established the company as a leading provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. "
target parent: Wicks Group of Companies
target: CenterWatch, Inc.
CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, data about the global clinical trials industry and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2007 via Berkery

Jobson Medical Information LLC, acquired CenterWatch, Inc.

synopsis: The Thomson Corporation announced the sale of CenterWatch to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
buyer parent: The Wicks Group of Companies, L.L.C.
buyer: Jobson Medical Information LLC
Jobson Medical Information is a leading specialty healthcare communications, publishing, and medical education company. Jobson Medical Information produces a broad range of publications, educational programs, enduring educational materials, live events, symposia and websites. "
target parent: Thomson Corporation
target: CenterWatch, Inc.
CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2019 via BNC Analysis

Genstar Capital LLC, acquired Advarra

synopsis: Genstar Capital, a private equity firm focused on investments in financial services, healthcare, industrial technology, and software industries, has acquired Advarra, a leading provider of institutional review board, institutional biosafety committee, and research quality and compliance solutions that are critical to the drug development process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that actively invests in high quality companies. Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. "
target parent: Linden Capital Partners
target: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/21/2019 via BusinessWire

Xcenda, acquired Dymaxium, Inc.

synopsis: Xcenda, a part of AmerisourceBergen, announced the acquisition of Dymaxium, a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
buyer parent: AmerisourceBergen Corporation
buyer: Xcenda
Xcenda, part of AmerisourceBergen, is a strategic consultancy with 20+ years of experience applying real-world expertise in health economics and outcomes research, reimbursement, stakeholder insights, and market access consulting and communications. "
target: Dymaxium, Inc.
Dymaxium is a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/16/2017 via PR Newswire

Decision Resources Group, acquired Context Matters

synopsis: Decision Resources Group announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 15 offices in North America, Europe and Asia. "
target: Context Matters
Context Matters is led by a team with extensive experience in the pharma & biotech and financial & information sectors with deep operational familiarity of the issues facing the pharmaceutical industry and those following the industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/7/2016 via BNC Analysis

M3, Inc., will acquire Vidal Group

synopsis: Electra Partners’ portfolio company AXIO Group has received a binding offer from M3 Inc. to purchase Vidal Group, a European provider of reference drug information. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients with on-line access to up-to-date drug databases and related treatment-based information.
buyer: M3, Inc. (TSE:2413:$1,110.45)
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet. "
target parent: Electra Partners LLP
target: Vidal Group
Vidal Group is a leading European healthcare informatics and information systems company. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients across Europe with on-line access to up-to-date drug databases and related treatment-based information.
price ($mm)
$133
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/30/2016 via BNC Analysis

Affinity Equity Partners, will acquire MedicalDirector

synopsis: Leading Asian private equity firm Affinity Equity Partners agreed to acquire Sydney-based MedicalDirector (formerly Health Communication Network) from Australia’s Primary Health Care Ltd. MedicalDirector is a leading provider of clinical and enterprise software solutions to general practitioners, medical specialists and allied health professionals.
buyer: Affinity Equity Partners
Affinity Equity Partners is an independently-owned buyout fund manager comprising primarily the former investment professionals of UBS Capital Asia Pacific. They are pioneers in buyout investments in the Asia-Pacific region, with an established and widely recognised franchise. "
target parent: Primary Health Care Limited
target: MedicalDirector
MedicalDirector has been supporting healthcare professionals and improving health outcomes for more than 20 years. They provide software for practice management, optimizing patient outcomes, and access to Australia's most comprehensive and up-to-date pharmaceutical database.
price ($mm)
$119
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/26/2015 via Company Press Release

Inovalon, Inc., will acquire Avalere Health LLC

synopsis: Inovalon, a leading technology company providing cloud-based analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Avalere Health, Inc., a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
buyer: Inovalon, Inc. (INOV:$449.36)
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. "
target: Avalere Health LLC
Avalere Health, Inc. is a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
price ($mm)
$140
rev ($mm)
$47
EBITDA ($mm)
EV / rev
3.0x
EV / EBITDA
closed 12/4/2012 via BusinessWire

Decision Resources Group, acquired Abacus International

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, announced that it has acquired Abacus International, a pioneer in evidence-based global market access solutions for many of the world’s leading healthcare companies.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Abacus International
Abacus International is unique in its provision of services throughout the lifecycle of a pharmaceutical or medical device. They can provide tailored solutions to overcome each hurdle of the product development process, from pre-launch though to market access.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
closed 7/22/2010 via Company Press Release

CT Corsearch, acquired Edital

synopsis: CT Corsearch, the premier provider of clearance and protection solutions for trademark and brand professionals, announced it’s acquired Edital, the Questel trademark branch. This acquisition will create best-in-class solutions for managing a brand lifecycle globally—from creation to watching to protecting, maintaining and renewing a brand.
buyer parent: Wolters Kluwer NV
buyer: CT Corsearch
CT Corsearch provides high-quality, intuitive tools and expertise that trademark professionals need to effectively manage the trademark screening, search review and watching processes. "
target parent: Questel
target: Edital
Edital was established in Brussels in 1982 and acquired by Questel, a world leader in Intellectual Property in 2005. Its sole purpose has been to create global solutions for the Intellectual Property professional.
price ($mm)
rev ($mm)
$8
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 9/27/2007 via PR Newswire

Thomson Pharma, acquired Prous Science

synopsis: The Thomson Corporation, a leading provider of information solutions to business and professional customers worldwide, today announced that it has acquired Prous Science, a global leader in the provision of life sciences information solutions. Prous Science will become part of Thomson Scientific.
buyer parent: The Thomson Corporation
buyer: Thomson Pharma
Thomson Scientific & Healthcare provides integrated information solutions to researchers and librarians, physicians and pharmacists, and other professionals worldwide. "
target: Prous Science
Prous Science is a trusted source of information on which science depends to discover safer and more effective medicines. The company's products have evolved through the years from print journals to sophisticated electronic products incorporating the latest advances in IT.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/15/2007 via Company Description

MergerMarket, acquired Infinata, Inc.

synopsis: In September 2007, Mergermarket acquired Infinata, an information solutions and marketing analytics provider to the global financial service, life science, and high technology industries.
buyer parent: Pearson plc
buyer: MergerMarket
MergerMarket, part of Pearson's Financial Times Group, is an unparalleled, independent M&A intelligence tool used by the world's foremost financial institutions to originate deals. It provides proprietary intelligence on potential deal flow, potential mandates and valuations. "
target: Infinata, Inc.
Infinata is an innovative provider of information solutions and marketing analytics to the global financial service, life science, and high-tech industries. Our information suites include: BioPharm Insight, High Net Worth Insight, and Corporate Tracker.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/10/2007 via

Providence Equity Partners Inc., acquired Decision Resources, Inc.

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, announced today that Providence Equity Partners, a leading private equity firm with more than $21 billion under management, will acquire majority control of the Company.
buyer: Providence Equity Partners Inc.
Providence Equity Partners Inc. is a private investment firm specializing in equity investments in communications and media companies around the world. The principals of Providence Equity manage funds with approximately $21 billion in equity commitments. "
target parent: Boston Ventures Management, Inc.
target: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/6/2004 via PR Newswire

Boston Ventures Management, Inc., Castanea Partners, acquired Decision Resources, Inc.

synopsis: Castanea Partners and Boston Ventures Limited Partnership VI today announced the recapitalization of Decision Resources, Inc., with a total transaction value of $58 million. The Waltham, Massachusetts-based company is best known for its therapeutically-focused analyses of global pharmaceutical and biotechnology markets.
buyer: Boston Ventures Management, Inc.
buyer: Castanea Partners
Boston Ventures Management, LLC is a private equity firm that has been an active investor and financial partner to management teams in the media, entertainment, publishing and information and communications sectors since 1983, earning the firm a franchise position in the private equity community. "
target: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit.
price ($mm)
$58
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/16/2015 via BNC Analysis

Sudler & Hennessey, acquired System Analytic Ltd.

synopsis: Sudler & Hennessey, has acquired a majority stake in System Analytic for an undisclosed sum. Sudler is a global healthcare marketing and communications network, while London-based System Analytic’s database and online tools enable pharmaceutical companies to identify, map and engage key opinions leaders across a broad range of medical fields.
buyer parent: WPP Group, plc
buyer: Sudler & Hennessey
Sudler & Hennessey is one of the world's leading healthcare communications firms, developing strategic promotional and educational programmes for a broad array of healthcare brands. "
target: System Analytic Ltd.
System Analytic Ltd. owns and operates a database and online tools to help pharmaceutical companies to identify and engages opinion leaders. The company was incorporated in 2006 and is based in London, United Kingdom.
price ($mm)
rev ($mm)
$3
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
announced 10/7/2019 via BNC Analysis

Inflexion Private Equity Partners LLP, will acquire Pharmaspectra

synopsis: Inflexion Private Equity, a UK mid-market private equity firm, will acquire Pharmaspectra, a global provider of medical affairs data to the pharmaceutical and biotech industry. Pharmaspectra offers the world's largest database for medical scientific literature and biomedical literature.
buyer: Inflexion Private Equity Partners LLP
Inflexion is a UK mid-market private equity firm. They invest in high growth, entrepreneurial businesses and work with them to accelerate growth. Inflexion’s flexible approach allows it to back both majority and minority investments, typically investing £10m to £150m of equity in each deal. "
target: Pharmaspectra
Pharmaspectra is a global provider of medical affairs data to the pharmaceutical and biotech industry. Pharmaspectra offers the world's largest database for medical scientific literature and biomedical literature. Their web-based solutions analyze data across the entire medical continuum.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
closed 5/5/2010 via Company Press Release

Kenneth Getz, acquired CenterWatch, Inc.

synopsis: Ken Getz, the founder of CenterWatch—an industry-leading clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information.
buyer: Kenneth Getz
Ken Getz founded CenterWatch in 1994 and established the company as a leading provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. "
target parent: Wicks Group of Companies
target: CenterWatch, Inc.
CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, data about the global clinical trials industry and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2007 via Berkery

Jobson Medical Information LLC, acquired CenterWatch, Inc.

synopsis: The Thomson Corporation announced the sale of CenterWatch to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
buyer parent: The Wicks Group of Companies, L.L.C.
buyer: Jobson Medical Information LLC
Jobson Medical Information is a leading specialty healthcare communications, publishing, and medical education company. Jobson Medical Information produces a broad range of publications, educational programs, enduring educational materials, live events, symposia and websites. "
target parent: Thomson Corporation
target: CenterWatch, Inc.
CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2019 via BNC Analysis

Genstar Capital LLC, acquired Advarra

synopsis: Genstar Capital, a private equity firm focused on investments in financial services, healthcare, industrial technology, and software industries, has acquired Advarra, a leading provider of institutional review board, institutional biosafety committee, and research quality and compliance solutions that are critical to the drug development process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that actively invests in high quality companies. Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. "
target parent: Linden Capital Partners
target: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/21/2019 via BusinessWire

Xcenda, acquired Dymaxium, Inc.

synopsis: Xcenda, a part of AmerisourceBergen, announced the acquisition of Dymaxium, a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
buyer parent: AmerisourceBergen Corporation
buyer: Xcenda
Xcenda, part of AmerisourceBergen, is a strategic consultancy with 20+ years of experience applying real-world expertise in health economics and outcomes research, reimbursement, stakeholder insights, and market access consulting and communications. "
target: Dymaxium, Inc.
Dymaxium is a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/16/2017 via PR Newswire

Decision Resources Group, acquired Context Matters

synopsis: Decision Resources Group announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 15 offices in North America, Europe and Asia. "
target: Context Matters
Context Matters is led by a team with extensive experience in the pharma & biotech and financial & information sectors with deep operational familiarity of the issues facing the pharmaceutical industry and those following the industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/7/2016 via BNC Analysis

M3, Inc., will acquire Vidal Group

synopsis: Electra Partners’ portfolio company AXIO Group has received a binding offer from M3 Inc. to purchase Vidal Group, a European provider of reference drug information. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients with on-line access to up-to-date drug databases and related treatment-based information.
buyer: M3, Inc. (TSE:2413:$1,110.45)
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet. "
target parent: Electra Partners LLP
target: Vidal Group
Vidal Group is a leading European healthcare informatics and information systems company. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients across Europe with on-line access to up-to-date drug databases and related treatment-based information.
price ($mm)
$133
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/30/2016 via BNC Analysis

Affinity Equity Partners, will acquire MedicalDirector

synopsis: Leading Asian private equity firm Affinity Equity Partners agreed to acquire Sydney-based MedicalDirector (formerly Health Communication Network) from Australia’s Primary Health Care Ltd. MedicalDirector is a leading provider of clinical and enterprise software solutions to general practitioners, medical specialists and allied health professionals.
buyer: Affinity Equity Partners
Affinity Equity Partners is an independently-owned buyout fund manager comprising primarily the former investment professionals of UBS Capital Asia Pacific. They are pioneers in buyout investments in the Asia-Pacific region, with an established and widely recognised franchise. "
target parent: Primary Health Care Limited
target: MedicalDirector
MedicalDirector has been supporting healthcare professionals and improving health outcomes for more than 20 years. They provide software for practice management, optimizing patient outcomes, and access to Australia's most comprehensive and up-to-date pharmaceutical database.
price ($mm)
$119
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/26/2015 via Company Press Release

Inovalon, Inc., will acquire Avalere Health LLC

synopsis: Inovalon, a leading technology company providing cloud-based analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Avalere Health, Inc., a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
buyer: Inovalon, Inc. (INOV:$449.36)
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. "
target: Avalere Health LLC
Avalere Health, Inc. is a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
price ($mm)
$140
rev ($mm)
$47
EBITDA ($mm)
EV / rev
3.0x
EV / EBITDA
closed 12/4/2012 via BusinessWire

Decision Resources Group, acquired Abacus International

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, announced that it has acquired Abacus International, a pioneer in evidence-based global market access solutions for many of the world’s leading healthcare companies.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Abacus International
Abacus International is unique in its provision of services throughout the lifecycle of a pharmaceutical or medical device. They can provide tailored solutions to overcome each hurdle of the product development process, from pre-launch though to market access.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
closed 7/22/2010 via Company Press Release

CT Corsearch, acquired Edital

synopsis: CT Corsearch, the premier provider of clearance and protection solutions for trademark and brand professionals, announced it’s acquired Edital, the Questel trademark branch. This acquisition will create best-in-class solutions for managing a brand lifecycle globally—from creation to watching to protecting, maintaining and renewing a brand.
buyer parent: Wolters Kluwer NV
buyer: CT Corsearch
CT Corsearch provides high-quality, intuitive tools and expertise that trademark professionals need to effectively manage the trademark screening, search review and watching processes. "
target parent: Questel
target: Edital
Edital was established in Brussels in 1982 and acquired by Questel, a world leader in Intellectual Property in 2005. Its sole purpose has been to create global solutions for the Intellectual Property professional.
price ($mm)
rev ($mm)
$8
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 9/27/2007 via PR Newswire

Thomson Pharma, acquired Prous Science

synopsis: The Thomson Corporation, a leading provider of information solutions to business and professional customers worldwide, today announced that it has acquired Prous Science, a global leader in the provision of life sciences information solutions. Prous Science will become part of Thomson Scientific.
buyer parent: The Thomson Corporation
buyer: Thomson Pharma
Thomson Scientific & Healthcare provides integrated information solutions to researchers and librarians, physicians and pharmacists, and other professionals worldwide. "
target: Prous Science
Prous Science is a trusted source of information on which science depends to discover safer and more effective medicines. The company's products have evolved through the years from print journals to sophisticated electronic products incorporating the latest advances in IT.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/15/2007 via Company Description

MergerMarket, acquired Infinata, Inc.

synopsis: In September 2007, Mergermarket acquired Infinata, an information solutions and marketing analytics provider to the global financial service, life science, and high technology industries.
buyer parent: Pearson plc
buyer: MergerMarket
MergerMarket, part of Pearson's Financial Times Group, is an unparalleled, independent M&A intelligence tool used by the world's foremost financial institutions to originate deals. It provides proprietary intelligence on potential deal flow, potential mandates and valuations. "
target: Infinata, Inc.
Infinata is an innovative provider of information solutions and marketing analytics to the global financial service, life science, and high-tech industries. Our information suites include: BioPharm Insight, High Net Worth Insight, and Corporate Tracker.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/10/2007 via

Providence Equity Partners Inc., acquired Decision Resources, Inc.

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, announced today that Providence Equity Partners, a leading private equity firm with more than $21 billion under management, will acquire majority control of the Company.
buyer: Providence Equity Partners Inc.
Providence Equity Partners Inc. is a private investment firm specializing in equity investments in communications and media companies around the world. The principals of Providence Equity manage funds with approximately $21 billion in equity commitments. "
target parent: Boston Ventures Management, Inc.
target: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/6/2004 via PR Newswire

Boston Ventures Management, Inc., Castanea Partners, acquired Decision Resources, Inc.

synopsis: Castanea Partners and Boston Ventures Limited Partnership VI today announced the recapitalization of Decision Resources, Inc., with a total transaction value of $58 million. The Waltham, Massachusetts-based company is best known for its therapeutically-focused analyses of global pharmaceutical and biotechnology markets.
buyer: Boston Ventures Management, Inc.
buyer: Castanea Partners
Boston Ventures Management, LLC is a private equity firm that has been an active investor and financial partner to management teams in the media, entertainment, publishing and information and communications sectors since 1983, earning the firm a franchise position in the private equity community. "
target: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit.
price ($mm)
$58
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/16/2015 via BNC Analysis

Sudler & Hennessey, acquired System Analytic Ltd.

synopsis: Sudler & Hennessey, has acquired a majority stake in System Analytic for an undisclosed sum. Sudler is a global healthcare marketing and communications network, while London-based System Analytic’s database and online tools enable pharmaceutical companies to identify, map and engage key opinions leaders across a broad range of medical fields.
buyer parent: WPP Group, plc
buyer: Sudler & Hennessey
Sudler & Hennessey is one of the world's leading healthcare communications firms, developing strategic promotional and educational programmes for a broad array of healthcare brands. "
target: System Analytic Ltd.
System Analytic Ltd. owns and operates a database and online tools to help pharmaceutical companies to identify and engages opinion leaders. The company was incorporated in 2006 and is based in London, United Kingdom.
price ($mm)
rev ($mm)
$3
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
announced 10/7/2019 via BNC Analysis

Inflexion Private Equity Partners LLP, will acquire Pharmaspectra

synopsis: Inflexion Private Equity, a UK mid-market private equity firm, will acquire Pharmaspectra, a global provider of medical affairs data to the pharmaceutical and biotech industry. Pharmaspectra offers the world's largest database for medical scientific literature and biomedical literature.
buyer: Inflexion Private Equity Partners LLP
Inflexion is a UK mid-market private equity firm. They invest in high growth, entrepreneurial businesses and work with them to accelerate growth. Inflexion’s flexible approach allows it to back both majority and minority investments, typically investing £10m to £150m of equity in each deal. "
target: Pharmaspectra
Pharmaspectra is a global provider of medical affairs data to the pharmaceutical and biotech industry. Pharmaspectra offers the world's largest database for medical scientific literature and biomedical literature. Their web-based solutions analyze data across the entire medical continuum.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

By CenterWatch, Inc.


read more

FDAnews inc.

CenterWatch, Inc.

CenterWatch, Inc.

CenterWatch, Inc.

read more

CenterWatch, Inc.

ERT

ERT

CenterWatch, Inc.

CenterWatch, Inc.

Advarra

Dymaxium, Inc.

Context Matters

Vidal Group

MedicalDirector

Avalere Health LLC

Abacus International

Decision Resources Group

Edital

Prous Science

Infinata, Inc.

Decision Resources, Inc.

Decision Resources, Inc.

System Analytic Ltd.

Pharmaspectra

read more

CenterWatch, Inc.

ERT

ERT

CenterWatch, Inc.

CenterWatch, Inc.

Advarra

Dymaxium, Inc.

Context Matters

Vidal Group

MedicalDirector

Avalere Health LLC

Abacus International

Decision Resources Group

Edital

Prous Science

Infinata, Inc.

Decision Resources, Inc.

Decision Resources, Inc.

System Analytic Ltd.

Pharmaspectra

Geography
Matching Companies
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3.com
M3.com
M3.com is Japan's largest portal site dedicated to healthcare professionals. M3.com provides the latest medical news, overseas journal article summaries, and medical resources. The portal offers information on clinical trials and other services in the healthcare and pharmaceutical industries.
year
2019
rev ($mm)
$1,015.17
EBITDA ($mm)
$288.13
EBIT ($mm)
$275.64
Net Income ($mm)
$175.78
Employees
5165
  • drill down
  • watch
Ticker: TSE:6095
 
 
 
 
 
 
 
 
MedPeer,Inc.
MedPeer,Inc.
MedPeer provides appropriate services at every stage of the clinical process physicians are involved in day-to-day clinical operation. Drug Evaluation provides detailed peer reviews of prescription drugs, and Meet the Experts allows members to consult expert physicians in specific therapeutic areas.
year
2016
rev ($mm)
$9.13
EBITDA ($mm)
$0.94
EBIT ($mm)
$0.39
Net Income ($mm)
$0.20
Employees
44
  • drill down
  • watch
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3.com
M3.com
M3.com is Japan's largest portal site dedicated to healthcare professionals. M3.com provides the latest medical news, overseas journal article summaries, and medical resources. The portal offers information on clinical trials and other services in the healthcare and pharmaceutical industries.
year
2019
rev ($mm)
$1,015.17
EBITDA ($mm)
$288.13
EBIT ($mm)
$275.64
Net Income ($mm)
$175.78
Employees
5165
  • drill down
  • watch
Ticker: TSE:6095
 
 
 
 
 
 
 
 
MedPeer,Inc.
MedPeer,Inc.
MedPeer provides appropriate services at every stage of the clinical process physicians are involved in day-to-day clinical operation. Drug Evaluation provides detailed peer reviews of prescription drugs, and Meet the Experts allows members to consult expert physicians in specific therapeutic areas.
year
2016
rev ($mm)
$9.13
EBITDA ($mm)
$0.94
EBIT ($mm)
$0.39
Net Income ($mm)
$0.20
Employees
44
  • drill down
  • watch